Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 17/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.65 |
| ▸ | CA1 | P00915 | 1/20 | 0.65 |
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CA9 | Q16790 | 1/20 | 0.65 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17978468 | 0.86 | NOTUM (0.53) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL17076798 | 0.84 | NOTUM (0.71) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL30723667 | 0.84 | NOTUM (0.72) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL23059421 | 0.83 | NOTUM (0.66) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL17978484 | 0.82 | NOTUM (0.50) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL3760196 | 0.82 | NOTUM (0.50) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL17502287 | 0.82 | NOTUM (1.00) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL19211396 | 0.82 | NOTUM (1.00) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL20639902 | 0.82 | NOTUM (0.70) | NOTUMKDM4EMAPTL3MBTL1CA12 | |
| SCHEMBL17704937 | 0.82 | NOTUM (0.70) | NOTUMKDM4EMAPTL3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256461-B1 | UREA AND SULFONAMIDE DERIVATIVES AS HUMAN HELICASE DDX3 INHIBITORS USEFUL IN THE TREATMENT OF VIRAL DISEASES | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2023-09-13 | — | — | EP | disclosed |
| EP-3432881-B1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIV SENESE (IT) | 2021-11-24 | — | — | EP | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | E-THERAPEUTICS PLC (GB) | 2021-08-05 | — | — | US | disclosed |
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-05-11 | — | — | US | disclosed |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2021-03-09 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENESE (IT) | 2020-05-07 | — | — | US | disclosed |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | AZIENDA OSPEDALIERA UNIVERSITARIA SENRESE (IT) | 2019-04-04 | — | — | US | disclosed |
| EP-3432881-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | Azienda Ospedaliera Universitaria Senese (IT) | 2019-01-30 | — | — | EP | disclosed |
| EP-2699572-B1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-2699579-B1 | PYRAZOLO[4,3-D]PYRIMIDINES USEFUL AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-10-07 | — | — | EP | disclosed |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-24 | — | — | US | disclosed |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| WO-2014060113-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2014-04-24 | — | — | WO | disclosed |
| EP-2699572-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Origenis GmbH (DE) | 2014-02-26 | — | — | EP | disclosed |
| CN-103492389-A | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors | ORIGENIS GMBH | 2014-01-01 | — | — | CN | disclosed |
| US-20120329785-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-20120329780-A1 | Novel kinase inhibitors | ORIGENIS GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012143143-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2012-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11000512-B2 | Use of DDX3 inhibitors as antiproliferative agents | DDX3X, DDX21, DDB1 | NOTUM 4246/4885KDM4E 1563/4885MAPT 4194/4885 |
| US-20210238139-A1 | MODULATORS OF TRYPTOPHAN CATABOLISM | TPH1, KYNU, TPH2 | NOTUM 1961/4885KDM4E 2770/4885MAPT 128/4885 |
| US-20150259340-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NOTUM 3651/4885KDM4E 1662/4885MAPT 470/4885 |
| US-20150266882-A1 | PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS | LRRK2, MYLK2, MYLK | NOTUM 4550/4885KDM4E 1409/4885MAPT 501/4885 |
| US-20200140398-A1 | HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS | DDX3X, DDX39B, DDX1 | NOTUM 4334/4885KDM4E 2372/4885MAPT 3432/4885 |
| US-20120329780-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK | NOTUM 3651/4885KDM4E 1662/4885MAPT 470/4885 |
| US-20120329785-A1 | Novel kinase inhibitors | LRRK2, MYLK2, MYLK3 | NOTUM 4349/4885KDM4E 1843/4885MAPT 634/4885 |
| US-10941121-B2 | Human helicase DDX3 inhibitors as therapeutic agents | DDX3X, DDX39B, DDX1 | NOTUM 4334/4885KDM4E 2372/4885MAPT 3432/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | NOTUM 3654/4885KDM4E 1645/4885MAPT 438/4885 |
| US-20190099403-A1 | USE OF DDX3 INHIBITORS AS ANTIPROLIFERATIVE AGENTS | DDX21, DDX3X, DDB1 | NOTUM 4300/4885KDM4E 1596/4885MAPT 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.